<DOC>
	<DOC>NCT01874470</DOC>
	<brief_summary>The purpose of ALLEGRO-HTN trial is to evaluate the safety and effectiveness of renal denervation in subjects with resistant hypertension by using Allegro renal denervation system</brief_summary>
	<brief_title>Renal Denervation by Allegro System in Patients With Resistant Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Antihypertensive Agents</mesh_term>
	<mesh_term>Diuretics</mesh_term>
	<mesh_term>Frovatriptan</mesh_term>
	<criteria>Age 18 65 years at time of randomization Stable medication regimen including 3 or more antihypertensive medications of different classes, including a diuretic (with no changes for a minimum of 4 weeks prior to screening) and no expected changes for at least 6 months 1) Office SBP and/or DBP ≥160/100 mm Hg ( ≥ 150/95 mmHg for type II diabetic patients) , 2) ABPM 24 hour average SBP and/or DBP ≥140 and/or 90 mmHg Main renal arteries with ≥4 mm diameter or with ≥20 mm treatable length (by visual estimation) eGFR≥45 mL/min/1.73 m2 Written informed consent Type 1 diabetes mellitus Secondary hypertension Has an implantable cardioverter defibrillator (ICD) or pacemaker Myocardial infarction, unstable angina pectoris, syncope, or a cerebrovascular accident within 6 months of the screening period Intravascular thrombosis or unstable atherosclerotic plaques Has hemodynamically significant valvular heart disease Pregnant, nursing, or planning to be pregnant Any serious medical condition that may adversely affect the safety of the participant or the study Currently enrolled in another investigational drug or device trial Angiographic Renal artery stenosis (≥50%) or renal artery aneurysm in either renal artery History of prior renal artery intervention including balloon angioplasty or stenting Multiple renal arteries where the main renal artery is estimated to supply &lt;75% of the kidney Main renal arteries with &lt;4 mm diameter or with &lt;20 mm treatable length (by visual estimation) Renal artery abnormalities</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>